🟢 Strong Evidence
Weekly injectable semaglutide delivers superior blood sugar control and weight loss compared to dulaglutide in patients with type 2 diabetes, according to a large UK population-based study. The research, published in The Lancet Regional Health – Europe, analyzed real-world effectiveness data from 6,103 adults starting either medication in UK primary care settings.
Key takeaways
- Semaglutide users achieved 0.20% greater HbA1c reduction compared to dulaglutide over 12 months
- Weight loss was 2.06 kg greater with semaglutide versus dulaglutide treatment
- Safety profiles were comparable between both weekly GLP-1 receptor agonists
- Benefits occurred in both trial-eligible and real-world patient populations
Study at a Glance
| Source | The Lancet Regional Health – Europe |
| Study type | Population-based cohort study |
| Sample size | N = 6,103 |
| Population | Adults with type 2 diabetes starting GLP-1 therapy |
| Country | United Kingdom |
Semaglutide shows superior effectiveness across key diabetes outcomes
Difference in clinical improvements at 12 months compared to dulaglutide
Source: The Lancet Regional Health – Europe, 2026 | Georgian Medical Journal News
Real-world evidence confirms clinical trial findings
The study, led by researchers at the University of Surrey, used the UK’s Clinical Practice Research Datalink to track 3,227 semaglutide users and 2,876 dulaglutide users between 2018 and 2022. This represents one of the largest head-to-head comparisons of these GLP-1 receptor agonists in routine clinical practice.
“The benefits we observed with semaglutide were consistent across both trial-eligible patients and those who typically wouldn’t qualify for randomized controlled trials,” according to the study authors. This finding addresses a critical gap between controlled trial populations and the diverse patients seen in everyday clinical practice.
Superior metabolic outcomes with comparable safety
At 12 months follow-up, semaglutide users experienced a mean additional HbA1c reduction of 0.20 percentage points compared to dulaglutide users (95% CI: -0.33 to -0.07). The World Health Organization considers HbA1c reductions of this magnitude clinically meaningful for diabetes management.
Weight loss differences were particularly pronounced, with semaglutide users losing an average of 2.06 kg more than dulaglutide users (95% CI: -3.24 to -0.88). Both medications showed similar rates of discontinuation and adverse events, suggesting comparable tolerability profiles.
Implications for diabetes treatment selection
The findings support UK clinical guidelines that increasingly favor semaglutide for patients with type 2 diabetes requiring injectable therapy. The study’s population-based design provides confidence that benefits translate beyond carefully selected trial participants to the broader diabetes population.
Both medications belong to the GLP-1 receptor agonist class, which works by mimicking hormones that regulate blood sugar and slow gastric emptying. The superior effectiveness of semaglutide may relate to its longer half-life and higher receptor binding affinity, according to pharmacological studies published in diabetes research journals.
Growing evidence base for personalized diabetes care
The research adds to mounting evidence supporting individualized approaches to diabetes medication selection. Previous meta-analyses have suggested similar patterns favoring semaglutide, but this study’s large sample size and real-world setting strengthen confidence in the findings.
Healthcare systems worldwide are grappling with optimal allocation of these newer, more expensive diabetes medications. The Centers for Disease Control and Prevention estimates that diabetes affects over 37 million Americans, with type 2 diabetes representing 90-95% of cases.
Semaglutide users achieved 0.20% greater HbA1c reduction and 2.06 kg additional weight loss compared to dulaglutide users at 12 months
— University of Surrey researchers (The Lancet Regional Health – Europe, 2026)
What this means
Frequently asked questions
How significant is a 0.20% difference in HbA1c reduction?
This magnitude of HbA1c improvement is considered clinically meaningful by diabetes organizations. Even small improvements in HbA1c translate to reduced risk of diabetes complications over time.
Are there differences in side effects between semaglutide and dulaglutide?
The study found comparable safety profiles between both medications. Common side effects for both drugs include nausea, vomiting, and gastrointestinal symptoms, particularly when starting treatment.
Should all patients switch from dulaglutide to semaglutide?
Treatment decisions should always involve individual consultation with healthcare providers. Patients who are stable and responding well to dulaglutide may not need to switch medications.
This population-based evidence strengthens the case for semaglutide as a first-line choice among weekly GLP-1 receptor agonists for type 2 diabetes. As healthcare systems continue optimizing diabetes care pathways, such real-world effectiveness data becomes increasingly valuable for evidence-based prescribing decisions. The study’s inclusion of both trial-eligible and non-eligible patients provides reassurance that benefits extend across the diverse diabetes population seen in routine clinical practice.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
